Eli Lilly and Sanofi Backed Scribe Therapeutics Surges Nearly 50% in Upsized IPO
Scribe Therapeutics, a gene therapy developer backed by pharmaceutical giants Eli Lilly (LLY) and Sanofi (SNY), surged nearly 50% on its first day as a publicly traded company. The initial public offering was upsized to raise more capital than initially planned, reflecting strong investor demand for the biotech firm's innovative approach in genetic medicine. The IPO success highlights growing interest in gene therapy and advanced treatments within the healthcare sector. Scribe’s collaboration with industry leaders like Eli Lilly and Sanofi has positioned it as a promising player in this emerging field.
Topics: gene therapy IPO stock price movement